Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains

Maja Stanojevic, Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center, Washington, DC, USA.
Ashley Geiger, Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center, Washington, DC, USA.
Brita Ostermeier, Institute for Biomedical Sciences, George Washington University, Washington, DC, USA.
Danielle Sohai, Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center, Washington, DC, USA.
Christopher Lazarski, Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center, Washington, DC, USA.
Haili Lang, Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center, Washington, DC, USA.
Mariah Jensen-Wachspress, Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center, Washington, DC, USA.
Kathleen Webber, Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center, Washington, DC, USA.
Peter Burbelo, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA.
Jeffrey Cohen, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA.
Michael D. Keller, Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center, Washington, DC, USA.
Catherine M. Bollard, Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center, Washington, DC, USA. Electronic address: cbollard@childrensnational.org.
Conrad Russell Cruz, Program for Cell Enhancement and Technologies for Immunotherapy, Children's National Medical Center, Washington, DC, USA. Electronic address: ccruz@childrensnational.org.

Document Type

Journal Article

Publication Date

1-1-2022

Journal

Cytotherapy

Volume

24

Issue

1

DOI

10.1016/j.jcyt.2021.07.006

Keywords

COVID-19 variants; SARS-CoV-2; T-cell responses to coronavirus; vaccination

Abstract

Although most studies describing coronavirus disease 2019 vaccine responses have focused on antibodies, there is increasing evidence that T cells play a critical role. Here the authors evaluated T-cell responses in seronegative donors before and after vaccination to define responses to the severe acute respiratory syndrome coronavirus 2 reference strain as well as to mutations in the variant strains Alpha/B.1.1.7 and Beta/B.1.351. The authors observed enhanced T-cell responses to reference and variant spike strains post-vaccination.

Department

Pediatrics

Link to Full Text

Share

COinS